Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III Study of AK160 in Patients With Dupuytren's Contracture

Trial Profile

Phase III Study of AK160 in Patients With Dupuytren's Contracture

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 Mar 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Collagenase clostridium histolyticum (Primary)
  • Indications Dupuytren's contracture
  • Focus Registrational; Therapeutic Use
  • Acronyms CORD-J
  • Sponsors Asahi Kasei
  • Most Recent Events

    • 03 Jul 2015 Asahi Kasei Pharma Corporation has received approval for manufacture and sale of collagenase clostridium histolyticum [XIAFLEX] for the treatment of Dupuytren's contracture in Japan, according to media release.
    • 31 Jul 2014 Asahi Kasei Pharma Corporation has completed a regulatory submission for XIAFLEX for Dupuytren's contracture in Japan, and a PMDA review is expteced to be completed by mid 2015, according to an Auxilium Pharmaceuticals media release.
    • 30 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top